MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Hendrix, Craig W ^a   Chen, Beatrice A ^b   Guddera, Vijayanand ^c   Hoesley, Craig ^d   Justman, Jessica ^e   Nakabiito, Clemensia ^f   Salata, Robert ^g   Soto Torres, Lydia ^h   Patterson, Karen ⁱ   Minnis, Alexandra M ^j,k   Gandham, Sharavi ^l   Gomez, Kailazarid ^m   Richardson, Barbra A ⁱ   Bumpus, Namandje N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d University of Alabama at Birmingham   (United States)

^e Department of Medicine   (United States)

^f MU JHU Research Collaboration   (Uganda)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j RTI INTERNATIONAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l SCHARP   (United States)

^m FAMILY HEALTH INTERNATIONAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED RNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR DIPHOSPHATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY FLUID; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED HEADACHE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; GEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOPHOSPHATEMIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PHOSPHORYLATION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; ORGANOPHOSPHONATES; PHOSPHOROUS ACIDS; PHOSPHORYLATION; RECTUM; TABLETS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84873858944     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055013     Document Type: Article

References (35)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med.
5. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med.
6. MTN. (2011) MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. In: Network MT, editor. Web site article.
7. MTN. (2011) MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women.
8. Donnell D, Baeten J, Hendrix CW, Bumpus N, Bangsberg D, et al. (2012) Detectable plasma levels over time in a pre-exposure prophylaxis clinical trial: the Partners PrEP Study. Microbicides 2012. Sydney.
9. Karim SS, Kashuba AD, Werner L, Karim QA, (2011) Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378: 279-281.
10. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA,et al. (2012 (In Press)) Adherence and acceptability in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav.
11. Mitchell C, Paul K, Agnew K, Gaussman R, Coombs RW, et al. (2011) Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J Clin Microbiol 49: 735-736.
12. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, et al. (2011) A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 6: e16475.
13. King T, Bushman L, Kiser J, Anderson PL, Ray M, et al. (2006) Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci 843: 147-156.
14. Simiele M, D'Avolio A, Baietto L, Siccardi M, Sciandra M, et al. (2011) Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob Agents Chemother 55: 2976-2978.
15. Reagan JW, Hamonic MJ, Wentz WB, (1957) Analytical study of the cells in cervical squamous-cell cancer. Lab Invest 6: 241-250.
16. Reagan JW, Bell BA, Neuman JL, Scott RB, Patten SF, (1961) Dysplasia in the uterine cervix during pregnancy: an analytical study of the cells. Acta Cytol 5: 17-29.
17. Blaskewicz CD, Pudney J, Anderson DJ, (2011) Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia. Biol Reprod 85: 97-104.
18. Hendrix CW, Minnis A, Guddera V, Riddler S, Salata R, et al. (2011) MTN-001: A Phase 2 Cross-Over Study of Daily Oral and Vaginal Tenofovir in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations. 18th Conference on Retroviruses and Opportunistic Infections February 27-March 2, 2011 Boston, MA (Abstract 35LB). Boston, MA.
19. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, et al. (2001) Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 45: 2733-2739.
20. Kearney BP, Flaherty JF, Shah J, (2004) Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43: 595-612.
21. Hawkins T, Veikley W, St Claire RL, 3rd, Guyer B, Clark N, et al (2005) Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 39: 406-411.
22. Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, et al. (2009) Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 53: 1937-1943.
23. Nuttall J, Kashuba A, Wang R, White N, Allen P, et al. (2012) Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 56: 103-109.
24. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, et al. (2007) Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21: 1899-1907.
25. Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, et al. (2011) A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 6: e25974.
26. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, et al. (2011) Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 66: 240-250.
27. Louissaint N, Cao Y, Tannenbaum S, Skipper P, Liberman R, et al. (2011) Single dose 14C-Tenofovir Distribution into Blood, Colon, and Vagina in Healthy Volunteers. Keystone Symposium: Protection from HIV: Targeted Intervention Strategies. Whistler, British Columbia, Canada.
28. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. (2011) Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 3: 112re114.
29. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, et al. (2012) Innate Immune Activation Enhances HIV Acquisition in Women, Diminishing the Effectiveness of Tenofovir Microbicide Gel. J Infect Dis 206: 993-1001.
30. Robbins BL, Wilcox CK, Fridland A, Rodman JH, (2003) Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 23: 695-701.
31. Balzarini J, Van Herrewege Y, Vanham G, (2002) Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 16: 2159-2163.
32. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A, (1998) Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42: 612-617.
33. Gao WY, Agbaria R, Driscoll JS, Mitsuya H, (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 269: 12633-12638.
34. Mohamed AS, Becquart P, Hocini H, Metais P, Kazatchkine M, et al. (1997) Dilution assessment of cervicovaginal secretions collected by vaginal washing to evaluate mucosal shedding of free human immunodeficiency virus. Clinical and Diagnostic Laboratory Immunology 4: 624-626.
35. Belec L, Meillet D, Levy M, Georges A, Tevi-Benissan C, et al. (1995) Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol 2: 57-61.